Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06543537 · ClinicalTrials.gov registry record · NA
Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer
A NA study of Ovarian Cancer and Ovarian Neoplasms, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 112
- Enrollment target
- 1
- Study location
NCT06543537: Recruiting NA study of Ovarian Cancer and Ovarian Neoplasms, sponsored by Dana-Farber Cancer Institute.
NCT06543537 is a NA study of Ovarian Cancer and Ovarian Neoplasms that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 112 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06543537, a NA study of Ovarian Cancer and Ovarian Neoplasms, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 112 participants
- Enrollment target
- 1
- Study location
Study Summary
This research is being done to test a new communication tool for people with ovarian cancer, caregivers, and clinicians. The name of the intervention in this research study is: -Collaborative Agenda-Setting Intervention (CASI)
Primary Outcome
The proportion of approached participants that are enrolled. Feasibility of an efficacy trial is defined as ≥60% enrollment among approached participants.
Conditions Studied
Interventions
- BEHAVIORAL Collaborative Agenda-Setting Intervention
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2025-01-17 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
What NCT06543537 shows while recruiting
NCT06543537 is an interventional study that assigns participants to a tested intervention. The registered 112 participants enrollment target is mid-sized for trials with a published cap, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (85% lower).
The record links to 3 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which Collaborative Agenda-Setting Intervention is the first listed.
NCT06543537 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06543537 about?
NCT06543537 is a clinical study titled "Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer". This research is being done to test a new communication tool for people with ovarian cancer, caregivers, and clinicians. The name of the intervention in this research study is: -Collaborative Agenda-Setting Intervention (CASI)
What is the current status of trial NCT06543537?
This trial is currently recruiting. It is a NA study. The enrollment target is 112 participants. The study started on 2025-01-17. Estimated completion is 2026-12-31.
What conditions does trial NCT06543537 study?
This clinical trial studies the following conditions: Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma.
What interventions are being tested in trial NCT06543537?
The interventions under investigation include: Collaborative Agenda-Setting Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT06543537?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06543537 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06543537's enrollment target sits among peer trials
112 140th of 322 higher than 182 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ASk Questions in GYnecologic Oncology (ASQ-GYO)
RECRUITING · NA
-
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
RECRUITING · NA
-
Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women
RECRUITING · NA
-
REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors
RECRUITING · NA
-
Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics
RECRUITING · NA
-
Comprehensive Yoga Therapy Based Lifestyle Prehabilitation Program for Women With Ovarian Cancer
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04511013 · 112 participants · Phase 2
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- NCT04551560 · 112 participants · NA
Stress and Congestive Heart Failure
- NCT04872166 · 112 participants · Phase 1
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
- NCT05024773 · 112 participants · Phase 3
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI